HK1231482A1 - 用於治療炎症的作用於多種前列腺素受體的拮抗劑 - Google Patents

用於治療炎症的作用於多種前列腺素受體的拮抗劑

Info

Publication number
HK1231482A1
HK1231482A1 HK17105261.2A HK17105261A HK1231482A1 HK 1231482 A1 HK1231482 A1 HK 1231482A1 HK 17105261 A HK17105261 A HK 17105261A HK 1231482 A1 HK1231482 A1 HK 1231482A1
Authority
HK
Hong Kong
Prior art keywords
inflammation
treatment
prostaglandin receptors
antagonists acting
multiple prostaglandin
Prior art date
Application number
HK17105261.2A
Other languages
English (en)
Inventor
Jose L Martos
David F Woodward
Jenny W Wang
Steven Dabbs
Jussi J Kangasmetsa
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1231482A1 publication Critical patent/HK1231482A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK17105261.2A 2014-01-27 2017-05-24 用於治療炎症的作用於多種前列腺素受體的拮抗劑 HK1231482A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931756P 2014-01-27 2014-01-27
PCT/US2015/013119 WO2015113057A1 (en) 2014-01-27 2015-01-27 Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

Publications (1)

Publication Number Publication Date
HK1231482A1 true HK1231482A1 (zh) 2017-12-22

Family

ID=52463197

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105261.2A HK1231482A1 (zh) 2014-01-27 2017-05-24 用於治療炎症的作用於多種前列腺素受體的拮抗劑

Country Status (5)

Country Link
US (2) US9365569B2 (zh)
EP (1) EP3099667B1 (zh)
CA (1) CA2945687A1 (zh)
HK (1) HK1231482A1 (zh)
WO (1) WO2015113057A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor
WO2023110710A1 (en) 2021-12-13 2023-06-22 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
AU2003219690A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
WO2005040128A1 (en) 2003-10-24 2005-05-06 Glaxo Group Limited Heterocyclyl compounds
GB0614423D0 (en) 2006-07-20 2006-08-30 Rolls Royce Plc Method for characterising the profile of a surface
WO2008098978A2 (en) 2007-02-16 2008-08-21 Glaxo Group Limited Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
KR101269393B1 (ko) 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 페닐프로피온산 유도체 및 이의 용도
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
JP5263131B2 (ja) 2009-11-30 2013-08-14 ブラザー工業株式会社 定着装置
AR079553A1 (es) * 2009-12-21 2012-02-01 Novartis Ag Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2860382C (en) 2011-12-21 2017-09-12 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response

Also Published As

Publication number Publication date
US20170096423A1 (en) 2017-04-06
EP3099667B1 (en) 2017-11-01
US9365569B2 (en) 2016-06-14
US9657018B2 (en) 2017-05-23
US20150210689A1 (en) 2015-07-30
CA2945687A1 (en) 2015-07-30
WO2015113057A1 (en) 2015-07-30
EP3099667A1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
IL253197A0 (en) Methods for the treatment of sphingosine-1-phosphate receptor 1-related conditions
PL3177723T3 (pl) Aptamery do zastosowania przeciwko chorobom związanym z autoprzeciwciałem
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
ZA201701644B (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PL3234298T3 (pl) Połączenie gwintowe
IL277068B (en) A cellular method for determining the potency of defibrotide
IL248267B (en) A process for preparing converted cycloserines
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
HK1231482A1 (zh) 用於治療炎症的作用於多種前列腺素受體的拮抗劑
IL249311A0 (en) You will notice for an oral infection
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201517643D0 (en) Dosage form for melatonin
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201508787D0 (en) Pharmaceutically active compounds
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders
GB201416462D0 (en) Compound for use
TWM489613U (en) Shower sprinkler structure
GB201501696D0 (en) Pharamaceutical Compounds